KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Name: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
Published: 2020
License: Public Domain

Merck Sharp & Dohme LLC · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

carcinoma

carcinoma, non-small-cell lung, programmed cell death receptor 1 (pd-1, pd1), programmed cell death receptor ligand 1 (pd-l1, pdl1), programmed cell death receptor ligand 2 (pd-l2, pdl2), interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Related documents